Patients who experienced cardiovascular side effects during cancer therapy with carfilzomib for multiple myeloma had relapsed multiple myeloma, so have be previously treated with other cancer therapies. The present is a single center cohort study to evaluate early cardiovascular effects of administration of irreversible proteasome inhibitor carfilzomib in naïve patients. We included 24 patients and collected cardiovascular side effects, echocardiographic parameters and endothelial function at baseline and after 4 cycles. At early follow up we observed increase in blood arterial pressure values (mean change in systolic pressure of 10 mmHg (P-value < 0.01; diastolic arterial pressure and mean arterial pressure of 3.3 mmHg and 5.4 mmHg, both P-value < 0.01). Reactive hyperemia PAT index was reduced in the whole cohort by a mean of 0.46 points (P-value < 0.01); diastolic function was changed: E-wave-deceleration-time (EDT) was reduced by 49,96 ± 31 ms, P-value < 0.05 and early diastolic tissue Doppler velocity (e′) by a mean value of 1.46 cm/s, P -value 0.04.
Introduction
Carfilzomib (CFZ) and bortezomib (BTZ) are now approved in European countries for therapy of multiple myeloma. Ixazomib is current being approved, so data of cardiac effects are not yet available. Evidence suggest bortezomib and carfilzomib having different safety profiles: bortezomib can cause peripheral neuropathy, gastrointestinal toxicity and symptomatic hypotension, while carfilzomib may be responsible for cardiovascular side effects such as dyspnea, hypertension, and heart failure (Dick and Fleming, 2010; Dimopoulos et al., 2016; Gavazzoni et al., 2018; Niesvizky et al., 2013; Stewart et al., 2015; Van de Donk et al., 2016) . The main lack of evidence now is that in vivo cardiovascular effects of carfilzomib have been only demonstrated in patients with relapsed/refractory multiple myeloma (MM) previously treated with other therapy, unfit for comorbidities and older. The aims of the present study were to evaluate early effects of intra-venous administration of carfilzomib in a cohort of patients with newly diagnosed multiple myeloma, naïve to other chemotherapies.
Material and methods

Study cohort and chemotherapy
The present is an observational study including a cohort of patients with recent diagnosis of multiple myeloma, who were scheduled for therapy with irreversible proteasome inhibitor carfilzomib (Kyprolys). The patients were not previously treated with other chemotherapies and they were concomitantly recruited in hematology in a study comparing anticancer efficacy of different therapeutic schemes containing carfilzomib (recruitment period by November 2016 to July 2017). We selected patients scheduled for the same type of treatment: dose of carfilzomib of 20 mg/m2 iv in 1-2 days of cycle 1, then 36 mg/m2 iv once a day on 8-9, 15-16 of Cycle 1 and in all other cycles; lenalidomide at 25 mg daily dose and dexamethasone at 20 mg daily dose at 1, 2, 8, 9, 15, 16, 22 ,23 days of each cycle. Inclusion criteria were: patients > 18 years old and < 75 years old; newly diagnosed multiple myeloma; patients should have given their written consensus to this study participation. We excluded patients with: left ventricle systolic dysfunction, dilated, hypertrophic, infiltrative, restrictive cardiomyopathies, systemic amyloidosis with cardiac involvement; pericardial disease; chronic heart failure with New York Heart Association (NYHA) class > 2; signs and symptoms suggesting coronary artery disease or documented acute coronary event in the previous 12 months (even without structural heart disease); history of cerebrovascular events in the 12 months prior to the study; obesity (body mass index-BMI > 30 kg/m2) or cachexia (BMI < 21 kg/m 2 ); poor control of blood pressure values with chronic treatments (for this purpose, patients attached at the time of screening assessment the result of ambulatory blood pressure monitoring carried out before the first dose schedule); any associated condition which in the opinion of the investigator may prevent the complete carrying out of the study or may influence the results (chronic severe renal insufficiency, severe hepatic failure; severe chronic respiratory disease). This observational protocol was approved by local ethical committee.
Scheduled visits, clinical evaluations and classification of adverse events
All subjects received scheduled chemotherapy and were evaluated before starting first dose of first cycle of carfilzomib (screening and visit 0), and the day after the end of fourth cycle (visit 1). We collected data regarding: demographic characteristics, chronic cardiovascular therapy and its modification, arterial blood pressure, heart rate, reactive hyperemia index by EndoPAT system, cardiovascular side effects. Arterial pressure was assessed as result of ambulatory blood pressure monitoring (ABPM), performed at visit 0 and 1. Echocardiographic evaluations were performed using GE VIVID 6 and loops were processed by ad hoc software (EchoPAC GE Medical Systems); all measures were collected according to international guidelines of American and European Society of Echocardiography (Badano et al., 2018; Lang et al., 2015; Nagueh et al., 2016) . Cardiovascular side effects were collected as stratified in grade from 1 to 5 according the Common Terminology Criteria for Adverse Events (CTCAE) (see Table 1 ) (https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm, 2009). For endothelium-mediated dilation we used EndoPAT device (EndoPAT2000; Itamar Medical Ltd, Caesarea, Israel). This is a method based on non-invasive peripheral artery tonometry signal technology: probes are placed on the index fingers of each hand, to measure arterial pulsatile volume changes, secondary to changes in arterial tone. A blood pressure cuff is inflated on one arm for 5 min, temporarily occluding blood flow to the index finger. Release of the blood pressure cuff leads to a rapid increase of blood flow and through shear stress a release of nitric oxide by endothelium leading to downstream vasodilation. This last one is measured by EndoPAT device as an increase in amplitude of the PAT signal. The output of this method is the ratio between baseline signal and after ischemia (Reactive Hyperemia PAT Index, RHI). It is now well known to be related to cardiovascular long term events both in secondary prevention (Bonetti et al., 2004) and in patients with risk factors without known coronary artery disease (Axtell et al., 2010; Hamburg et al., 2008; Mahmud et al., 2009; Origliani and Modena, 2008; Rubinshtein et al., 2010; Shachor-Meyouhas et al., 2007) . It has to be noted that measurement from the contralateral finger probe is elaborated as "control" for endothelium-independent changes in vascular tone. Moreover, for further reduction of external factors and daily excursions, the evaluation of endothelial function at visit 0 and 1 were performed at same hour in day (before administration of pre-scheduled dose of iv carfilzomib). By using automatically software elaborated signals and these artifices EndoPAT allows a less operator dependent estimation of endothelial function than other noninvasive evaluation of vascular properties (such as flow mediated dilation) (Hamburg et al., 2008) .
End-point of the study
End point of this preliminary analysis was evaluation of early cardiovascular effects (after 4 months) of administration of carfilzomib.
Statistical analysis
For continuous variables, testing for normality was performed by Kolmogorov-Simirnov test. Continuous variables were expressed as the mean value with standard deviation (S.D.) and compared with paired sample Student's T test and Wilcoxon test. Categorical variable were expressed as frequency and percentages. Statistical analysis was performed using SPSS for Windows, version (SPSS,version 20, Inc.,Chicago, IL, USA); a P-value < 0.05 was considered statistically significant. We tested the relation between baseline characteristics of patients and cardiovascular adverse events (from grade 0-4) in a univariate analysis and then in multivariate analysis. Results are demonstrated as Odds Ratio (OR) and 95% confidence intervals (CI).
Results
Patients' baseline characteristics
From November 2016 to July 2017 27 patients have been evaluated; 3 patients were excluded at screening so a total of 24 patients were recruited in our observational protocol. Baseline characteristics of the patients are summarized in Table 2 . Patients were 57,6 ± 5,32 years old and they had normal values of mean arterial pressure, reactive hyperemia index and echocardiographic parameters (Table 3 ).
In the following paragraphs, we have described cardiovascular effects classified into vascular and myocardial and in the last part of this session the same are presented according to recommended international classification of cardiovascular adverse events.
Arterial blood pressure and endothelial function
From the baseline to visit 1 we observed increase in systolic and mean arterial pressure. Mean increase in arterial systolic pressure was of 10 mmHg (CI 95%: 6.4-13.6), strongly statistically significant (P value < 0.01); diastolic arterial pressure and mean arterial pressure were increased too (mean raising were respectively 3.3 mmHg and 5.4 mmHg, both P value < 0.01). Heart rate was higher than baseline during follow up, but we could suggest that this short term effect could be more related to concomitant corticosteroid assumption, whose earliest effects are mostly sympathomimetic.
Reactive hyperemia PAT index was reduced in the whole cohort by Death related to AE a mean of 0.46 points (P value < 0.01). 6 patients had reduction of RHI below the cut off of 1.67.
Echocardiographic parameters
In our cohort, after 4 cycles of therapy we observed main change in E-wave-deceleration-time (EDT) with a drop of -49,96 ± 31 ms, P value < 0.05. Other echocardiographic parameters showed early statistically significant alteration. Early diastolic tissue Doppler velocity dropped (e', cm/s) by a mean value of 1.46 cm/s (CI 95% 2,7-0.17, P value 0.04), with concomitant increase in E/e' ratio (by a mean of 1,46 ± 2.1, P value 0.03). Pulmonary artery systolic pressure (mmHg) was higher by a mean of 3,04 ± 1.3 (P-value 0.04).
In 2 of 24 patients we observed E/e' value > 13, with dyspnea and pulmonary hypertension needing for diuretic. No ejection fraction nor longitudinal tissue deformation were significantly altered during the first four cycles of carfilzomib. Table 4 shows echocardiographic parameters at baseline and the main change of each one.
Adverse events according to National Cancer Institute Cancer Therapy Evaluation Program classification (CTEP) and their clinical predictors
We collected and classified events of any grade: those not requiring medical intervention or adjustment of therapy (grade 1) and those that required (grade at least 2). In Table 5 are represented events after 4 cycles of therapy. In our population of patients naïve to any chemotherapies, at early term we did not observe events of grade 3 or 4, requiring suspension of therapy. Patients had mostly arterial hypertension of grade 2 and heart failure of grade 1. We performed univariate analysis for testing predictors of these events and we found that endothelial dysfunction at baseline (RHI < 1.67), history of arterial hypertension and age were significantly related to combined events. Texting these variables in multivariate regression, age and low RHI were independently associated to events (OR 1.9, CI 95% 0.05-5.804, P-value: 0.038 for RHI < 1.67; OR 1,4, CI 95%0.99-2.56, P -value: 0.04 for age) (See Table 6 ).
Discussion
This is the first study on patients with newly diagnosed multiple myeloma treated with carfilzomib, lenalidomide, dexamethasone as first line therapy. Here we have analyzed the short term effects on vascular and myocardial function.
After four cycles of therapy (corresponding to 4 months) we assessed a significant increase in systolic arterial pressure by a mean of 10 mmHg ± 8.3 mmHg (P-value 0.0001); both diastolic and mean arterial pressure were increased too (mean raising were respectively 3.3 mmHg and 5.4 mmHg, both P-value < 0.01). It has to be noted that patients in our cohort were treated with concomitant dexamethasone, so it seems to be difficult to separate effects of single drugs. However, the frequency of arterial hypertension during corticosteroid treatment has been estimated around 20% of subjects treated with at least 200 mg/day of hydrocortisone (dexamethasone > 20 mg/die); at these dosages the increase in pressure values (6-13 mmHg for systolic BP and 7-11 mmHg for diastolic BP) can be observed already after a few days of therapy (Sholter and Armstrong, 2000; Wei et al., 2004) . In a retrospective study, chronic intake of low-dose prednisone (total daily dose < 20 mg) did not alter arterial blood pressure (Souverein et al., 2004) . Moreover it should be emphasized that dexamethasone has lowest mineral-corticoid -like activity and patients in our study received dexamethasone at 20 mg daily dose at day 1,2,8,9,15,16,22,23 of each cycle. This free time between doses further reduces hydrosaline-retention effect.
Reactive hyperemia PAT index was reduced in the whole cohort by a mean of 0.46 points (P-value < 0.01). The detection of a significant reduction in RH index could represent reduction in endothelial vasodilating properties. Indeed, it has been demonstrated by Rubinshtein R. et al. that magnitude of natural-logarithmic-scaled RH index in 270 outpatients was associated with adverse events rate (cardiac death, myocardial infarction, revascularization or cardiac hospitalization) during a 7 years follow-up (Rubinshtein, 2010) ; authors suggested that in lower risk population RHI could be related to long term events, even if the value is still above the cut off of 1.67. Therefore, the observation of a reduction of RHI could have important clinical implication by suggesting pathological mechanism of long term cardiovascular effects. Administration of scheme of therapy containing carfilzomib could early affect endothelial function, reducing RHI and increasing vascular tone. These facts had already been suggested in previous in vitro and in vivo studies (Herrmann et al., 2007; Grandin et al., 2015; Rosenthal et al., 2016) . 72.9 ± 6.03 3.3 ± 3.9 1.03-5.5 0.001
Diastolic dysfunction was found to happen early in myocardial disease with proteasome deficiency (Herrmann et al., 2007 , Predmore et al., 2010 ; it seems to be related both to growth of protein aggregates that increase tissue's stiffness (Patterson et al., 2007) and to dysfunction of calcium control proteins that would increase tissue stiffness in a more "active" way (Thuerauf et al., 2001 ). In our experience most important short term echocardiographic alteration was in early wave deceleration time (EDT) that has dropped out of -49,96 ± 31 ms, P -value < 0.01. We found a significant reduction of early diastolic tissue velocity e´(mean reduction of 1.46 cm/s, P -value 0.04) and increase in E/eŕ atio (1,46 ± 2.1, P -value 0.03). Taking together these results, we can suppose that they are due to both direct effect of proteasome dysfunction in myocardial cells and indirect effects of proteasome dysfunction on vascular tone by increasing arterial blood pressure. So, hypertension-related cardiac organ damage is more pronounced when concomitantly protective mechanism is put out of functioning (in this case: proteasome inhibition in vascular and cardiac cells). We can speculate that it could be a proof of two-hit theory of cardiovascular damage of anticancer target therapy. Moreover, such important reduction in EDT could be due even to hydro-saline retention induced by corticosteroid concomitant therapy or to reduced left atrial function causing less pronounced systolic atrial function and increase in end diastolic atrial pressure (so increasing EDT velocity). Indeed, early involvement of atrial function has been related to clinical outcomes in other series of cancer patients (Moreno et al., 2016) By classifying events with common terminology criteria for adverse 19.4 ± 2.6 0.4 ± 0.5 − 0.9 to 1.2 0.07 Table 5 Cardiovascular side effects observed during follow up of 4 months (4 cycles). events, we did not observe any events of grade 3 or 4 (requiring temporary suspension of therapy). Patients had mostly arterial hypertension of grade 2 (21% of population) and heart failure of grade 1 (16%). Phase III study ASPIRE compared the combination of carfilzomib/lenalidomide/dexamethasone (KRd) with lenalidomide/dexamethasone (Rd) in 792 patients with relapsing multiple myeloma after 1-3 previous therapy lines. In this study adverse events of grade 3 occurred in 84% of patients with carfilzomib and 80% of patients in the control group. Adverse events greater than 3 included: dyspnea (2.8% vs 1.8%), heart failure (3.8% vs. 1.8%), myocardial ischemia (3.3% vs 2.1%), arterial hypertension (4.3% vs. 1.8%), pulmonary hypertension (2% vs < 1%), acute renal dysfunction (3.3% vs 3.1%) (Stewart et al., 2015) . More interesting, deaths due to cardiovascular events were the same in both groups, indicating that the most importance consequence of these events could be suspension of chemotherapy. Mean age of our cohort were 57,6 ± 5,32 so patients were younger than in ASPIRE in which 46% of patients were more than 65 years old. According to exclusion criteria, they did not have cardiovascular serious comorbidity at baseline other than hematological condition and not being previously treated with other therapies such as bortezomib. However, it has to be noted that in clinical trial the follow up was longer than our study (88 weeks in ASPIRE). Our results should be interpreted taking into account this fact and we can hypothesize that early effects we observed could precede the more severe ones observed in the trial. For patients treated with chemotherapies surveillance strategies allow clinicians to early detect cardiovascular damage, so starting ad hoc therapies and preventing treatment interruption (Zamorano et al., 2016) . In unselected patients treated with proteasome inhibitors it has been demonstrated the poor utility of serial screening with echocardiograms for predicting cardiovascular events (Russell et al., 2015) . Chari and Hajje (2014) in a small retrospective study reported that most of patients experiencing cardiovascular side effects during carfilzomib had a previous history of that specific cardiac or vascular event they experience. In other small studies (Grandin et al., 2015; Rosenthal et al., 2016) authors have hypothesized that cardiovascular toxicity could be explained by an endothelial pathogenic reversible creatinine increase (only partially correctable by hydration), acute increase in myocardial stretch markers (cardiac natriuretic peptides) and early absence of structural cardiac damage. In our experience, we tried to test the role of each baseline variable in predicting adverse events. In our cohort 40% of patients had hypertension at baseline. Despite this fact arterial hypertension was not independent predictor of events. We can suppose that it could be most due to two facts. First of all the small dimension of cohort that does not allow to point out the mere effect of hypertension by the effect of antihypertensive medications; second, we should take into account the absence of hypertension-related organ damage at baseline of our patients (cardiac hypertrophy), so the selection of patients with a low-intermediate cardiovascular risk profile. More interesting it could be the role of detecting endothelial dysfunction. An RHI lower than 1.67 at baseline was related to risk of any source of cardiac adverse events. This result is in line with other evidence that we have recently collected (Gavazzoni et al., 2018) : effects of proteasome inhibition could depend on 1) duration and total dose of exposition, 2) reversibility of effects (carfilzomib rather than bortezomib), 3) baseline level of proteasome activity in endothelial and myocardial cells. Indeed, genetic predisposition, acute and chronic external dangerous factors and oxidative stress are of great importance for predicting risk of cardiovascular side effect (Chen-Scarabelli et al., 2017; Forstermann and Munzel, 2006; Herrmann et al., 2007; Meiners et al., 2006; Qaqish et al., 2016; Stangl et al., 2004; Xu et al., 2007) .
Our results taken together could even suggest a practical approach to patients treated with new type of target cancer therapy. First of all, we should make patients achieving optimal control of their risk profile at baseline ("primordial prevention" of cardiovascular side effects). This can be reached by intensive treatment of blood pressure before first dose for achieving better than "normalized" arterial pressure and monitoring arterial pressure during therapy; this intensive approach could prevent grade 2 hypertension adverse events (SABP > 160 mmHg) that require suspension of therapy. Assessment of subclinical vascular damage and vascular reactivity (as we did by using EndoPAT) could be important to identify patients with suboptimal control of risk factors and lower baseline cardiovascular functional reserve, filling gap in evidence regard risk assessment ("primary prevention" of cardiovascular side effects) (Hamo et al., 2016) . Finally, it has to be noted that in our cohort we found early alteration of diastolic properties of myocardial tissue, suggesting that organ damage in the setting of exposure to type II chemotherapies could be earlier than in essential hypertension (such as for vascular-endothelial-growth factors inhibitors) (Plana et al., 2014) . Therefore ( "secondary prevention" of cardiovascular side effects) we must take into account benefits of antihypertensive therapies targeting organ damage instead of merely blood pressure level (renin-angiotensin system inhibitors rather than calciumchannels blockers or α1 antagonists, for example). All these considerations are of great importance in setting of cancer-therapy-relatedeffects type II, which are mediated by cardiovascular dysfunction: a baseline reduction in cardiovascular reserve is the most important predictor for clinical events, being the final effects mediated by multiple-hits.
Conclusion
Our results suggest administration of carfilzomib as first line therapy can early altered myocardial and vascular properties; the final effects in our cohort depend on grade of baseline endothelial vasodilation properties, history of hypertension and age. Chronic surveillance of cancer patients treated with new target therapies ("primordial" prevention) is needed for detecting these early dysfunction and taking adequate preventive measurements to avoiding grade 3 or 4 adverse events, that require immediate suspension of cancer therapy affecting patients' prognosis. We think that real life multicenter registries are needed for confirming these preliminary results, for getting more standardized protocols for evaluations and treatments of cardiovascular effects (primary and secondary prevention).
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